Blood Pressure in Treated Hypertensive Individuals With theMTHFR677TT Genotype Is Responsive to Intervention With Riboflavin
Open Access
- 1 June 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 61 (6) , 1302-1308
Abstract
Intervention with riboflavin was recently shown to produce genotype-specific lowering of blood pressure (BP) in patients with premature cardiovascular disease homozygous for the 677C→T polymorphism (TT genotype) in the gene encoding the enzyme methylenetetrahydrofolate reductase (MTHFR). Whether this effect is confined to patients with high-risk cardiovascular disease is unknown. The aim of this randomized trial, therefore, was to investigate the responsiveness of BP to riboflavin supplementation in hypertensive individuals with the TT genotype but without overt cardiovascular disease. From an available sample of 1427 patients with hypertension, we identified 157 with theMTHFR677TT genotype, 91 of whom agreed to participate in the trial. Participants were stratified by systolic BP and randomized to receive placebo or riboflavin (1.6 mg/d) for 16 weeks. At baseline, despite being prescribed multiple classes of antihypertensive drugs, >60% of participants with this genotype had failed to reach goal BP (≤140/90 mm Hg). A significant improvement in the biomarker status of riboflavin was observed in response to intervention (PP=0.033) in systolic BP was observed, with pre- and postintervention values of 141.8±2.9 and 137.1±3.0 mm Hg (treatment group) and 143.5±3.0 and 144.3±3.1 mm Hg (placebo group), whereas the treatment effect in diastolic BP was not significant (P=0.291). In conclusion, these results show that riboflavin supplementation targeted at hypertensive individuals with theMTHFR677TT genotype can decrease BP more effectively than treatment with current antihypertensive drugs only and indicate the potential for a personalized approach to the management of hypertension in this genetically at-risk group.Clinical Trial Registration—: URL:http://www.clinicaltrials.gov. Unique identifier: ISRCTN23620802.Keywords
This publication has 33 references indexed in Scilit:
- Strong association of methylenetetrahydrofolate reductase gene C677T polymorphism with hypertension and hypertension-in-pregnancy in Chinese: a meta-analysisJournal of Human Hypertension, 2011
- Genome-Wide Association Studies Will Unlock the Genetic Basis of HypertensionHypertension, 2010
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Genome-wide association study of blood pressure and hypertensionNature Genetics, 2009
- Genome-wide association study identifies eight loci associated with blood pressureNature Genetics, 2009
- Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trialsBMJ, 2008
- Global burden of blood-pressure-related disease, 2001The Lancet, 2008
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trialsThe Lancet, 2000
- A Clinical Trial of the Effects of Dietary Patterns on Blood PressureNew England Journal of Medicine, 1997